AXL and glioma: Irrespective of the nature of Wnt pathway involvement with BRAFV600E glioma cell adaptation to BRAFV600E inhibitor treatment, our current work provides information important to improving the duration and/or extent of BRAFV600E glioma therapy by interfering with compensatory cell responses that involve increasing Axl and EGFR activities.